MedPath

Sanofi

Sanofi logo
🇫🇷France
Ownership
Public
Employees
87.9K
Market Cap
$141.3B
Website
http://www.sanofi.com
Introduction

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

ESTEVE Acquires Caprelsa Rights from Sanofi to Expand Rare Cancer Treatment Portfolio

ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries for treating aggressive and symptomatic medullary thyroid cancer in adults and children above 5 years of age.

Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen

Vor Bio acquired exclusive global rights (excluding Greater China) to develop and commercialize telitacicept, a dual-target fusion protein approved in China for multiple autoimmune diseases including generalized myasthenia gravis.

CDC's Reconstituted Vaccine Advisory Panel Votes to Eliminate Thimerosal from All Flu Vaccines

The newly appointed Advisory Committee on Immunization Practices (ACIP) voted 5-1 to recommend thimerosal-free influenza vaccines for all age groups, despite the preservative being present in only 6% of U.S. flu vaccines.

MIRA Pharmaceuticals Unveils Preclinical Data for SKNY-1, Targeting Obesity and Smoking Cessation Without CNS Side Effects

MIRA Pharmaceuticals announced new in vitro preclinical data from Eurofins demonstrating SKNY-1's potential as a first-in-class oral therapy for obesity and nicotine addiction without central nervous system side effects.

Sanofi Advances Kymera's Next-Generation IRAK4 Degrader KT-485 to Clinical Testing

Sanofi has selected Kymera's KT-485, a next-generation oral IRAK4 degrader, to advance into Phase 1 clinical testing next year for immuno-inflammatory diseases.

Sanofi Invests $25 Million in Adagene's SAFEbody Platform for Next-Generation Cancer Immunotherapy

Sanofi has committed up to $25 million in strategic investment to Adagene, extending the biotech's cash runway into 2027 and supporting clinical development of its lead SAFEbody candidate muzastotug.

Sanofi Licenses Dual JAK/SYK Inhibitor Gusacitinib from Formation Bio in €545 Million Deal

Sanofi has licensed gusacitinib, an oral dual JAK/SYK inhibitor, from Formation Bio's subsidiary Libertas Bio in a deal worth up to €545 million including upfront payments, milestones, and low to mid-teen royalties.

Tharimmune Appoints New CEO and Board Members to Advance Opioid Antagonist TH104 Development

Tharimmune announced key leadership changes with Sireesh Appajosyula becoming CEO and Vincent LoPriore appointed Executive Chairman in June 2025.

UCB Announces $5 Billion U.S. Biologics Manufacturing Investment to Strengthen Supply Chain

UCB plans to invest $5 billion in a new state-of-the-art biologics manufacturing facility in the United States, creating 300 permanent high-skilled jobs and over 500 construction positions.

Comprehensive Analysis Reveals 943 Autoimmune Collaboration and Licensing Deals Across 30 Diseases from 2016-2025

A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.

© Copyright 2025. All Rights Reserved by MedPath